Register to Vote: Rock the Vote, powered by Credo Mobile

HOME

ABOUT US

OUR ISSUES

Federal Budget

Information & Access

Nonprofit Advocacy


PRESS ROOM

ACTION CENTER

PUBLICATIONS

THE WATCHER

OUR BLOGS


SIGN UP

Receive news, updates, and alerts!

DONATE

Help support our work


OTHER SITES

FedSpending.org

RTK NET

NPAction

Working Group on Community Right-to-Know

Citizens for Sensible Safeguards

Open the Government

OMB Watch Logo

"[P]eople acting in a group can accomplish things which no individual acting alone could even hope to bring about." - FDR

Home :  Regulatory Policy :  RegWatch : 
RegWatch:     

News & Analysis | REG•WATCH Blog | Press Room

 R    E    G    •    W    A    T    C    H 


Tuesday, December 04, 2007

Study Proves No Need for Conflicted FDA Panel Members

In March, FDA issued draft guidelines that would revise its criteria for determining whether scientific advisory committee members have financial conflicts of interest. FDA advisory committees are standing panels comprised of individuals considered experts in a particular field. They provide advice to FDA on matters such as drug and medical device safety.

While the guidelines would be a good step toward ensuring scientific integrity on FDA panels, they would also make it too easy for FDA to grant waivers to conflicted scientists. For example, if FDA determines an individual has a financial conflict, the guidance instructs agency personnel to ask: "Does the need for the individual's services outweigh the potential for a conflict of interest?" If the answer is "yes," the member could serve on the panel but could not vote.

FDA argues that certain individuals have unique experience and qualification and, regardless of financial conflicts, are necessary for the panel. In fact, FDA recently issued a report which concluded it would be too difficult to create conflict-free advisory panels.

But a new investigation by the Center for Science in the Public Interest (CSPI) debunks that myth. CSPI analyzed the same data FDA used for its study, but came to a different conclusion:

For each of the four advisory committees analyzed in the study, it would have taken a single FDA official just one week to replace all the advisers who had conflicts of interest with experts who do not have conflicts of interest, according to CSPI's analysis of the ERG data. Moreover, the FDA would be able to choose from nearly two potential unconflicted experts for every open slot. And, based on the same criteria for the expertise of potential committee members used in the study, these easily identifiable unconflicted experts would be more qualified than the ones eventually chosen, whether they had conflicts of interest or not.



Posted by Matt Madia



Entries by Theme

All Themes

Enforcement

About This Blog

Rollbacks

Safety

Industry Influence

Cost-Benefit Analysis

In Congress

Publications

Consumer Issues

Environment

Public Health

In the Courts

Oversight

In the White House

Most Recent Entries for RegWatch

Industry Pressuring EPA to Weaken Lead Rule

EPA Won't Keep Rocket Fuel out of Water

Roof Strength Rule Delayed Again

Bush Taking Credit for Whale Rule He Delayed

What Should the U.S. Do about China's Bad Milk?

Did OMB Block Asbestos Cleanup in Montana Town?

Whale Protection Rule Clears White House, 573 Days Later

EPA Just Kidding Around on Children's Health

White House, EPA Protecting Rocket Fuel Polluters

Pentagon Won't Clean up Its Messes

Archived Entries for Consumer Issues

August

July

May

April

March

February

January

December, 2007

November, 2007

October, 2007

September, 2007

August, 2007

July, 2007

June, 2007

May, 2007

April, 2007

March, 2007

February, 2007

January, 2007

December, 2006

November, 2006

October, 2006

September, 2006

August, 2006

May, 2006

April, 2006

February, 2006

January, 2006

December, 2005

November, 2005

October, 2005

September, 2005

August, 2005

July, 2005

June, 2005

May, 2005

April, 2005

March, 2005

February, 2005

January, 2005

December, 2004

November, 2004

October, 2004

September, 2004